CRISIL reaffirms Mankind Pharma AA+ on NCDs, withdraws two ratings
- Credit rating
Mankind Pharma (NSE: MANKIND) said in a filing on 29 Oct 2026 that CRISIL Ratings Limited reaffirmed Crisil AA+/Stable on non-convertible debentures of ₹400 crore and ₹2,100 crore. It also withdrew the rating on ₹2,500 crore of non-convertible debentures and the Crisil A1+ rating on ₹1,500 crore of commercial paper.
Key highlights
- Reaffirmed: ₹400 crore and ₹2,100 crore non-convertible debentures at Crisil AA+/Stable
- Withdrawn: ₹2,500 crore non-convertible debentures, last rated Crisil AA+/Stable
- Withdrawn: ₹1,500 crore commercial paper, last rated Crisil A1+
- CRISIL release dated 29 Oct 2026
Sign up to continue reading
Create a free account to read the rest of this article and the analysis that follows.
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
